Skip to content

Hematology Biobank: In Vitro Study of Blood Disorders

Hematology Biobank: In Vitro Study of Blood Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02442011
Enrollment
2000
Registered
2015-05-13
Start date
2014-01-31
Completion date
2030-01-31
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Disorders

Keywords

Hematology Biobank

Brief summary

This is a biorepository of blood specimens from subjects with different Hematological disorders.

Detailed description

There has been a marked increase in our knowledge of Blood Disorders in the last decade. Much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or DNA analyses. The study team proposes to set up a Hematology biobank, which will include patient histories, their medical progress and a linked but de-identified bank of blood samples. This will enable researchers to have a large database, which can be used to learn more about these diseases. The Hematology biobank will use whole blood, red blood cells, plasma, serum and/or DNA. Whole blood specimens, which by definition include the white cells that contain DNA, will be collected and stored in the biobank repository at the Institute for Clinical and Translational Research (ICTR) for future studies. Blood samples will be obtained from two sources: 1. Leftover/discarded whole blood samples that were obtained for standard of care. 2. Blood samples consisting of 1-5 tubes (3-20 ml of whole blood) from patients with written consent. When possible, these samples will be obtained during routine blood draws performed for a typical visit. It may be necessary to ask patients to specifically donate blood for the study.

Interventions

None listed

Sponsors

New York Blood Center
CollaboratorOTHER
Albert Einstein College of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Above 12 years of age and referred to the Hematology Division at Montefiore-Einstein * Under the care of a Montefiore-Einstein hematologist for a hematologic disorder

Exclusion criteria

\- Do not meet the Inclusion Criteria listed above

Design outcomes

Primary

MeasureTime frameDescription
Biobank5 yearsTo have specimens available for IRB approved studies

Countries

United States

Contacts

Primary ContactSwati Goel
swgoel@montefiore.org7189204137

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026